Company profile / BRIGHOTEL

Brigade Hotel Ventures earnings calls.

Other · 4 quarters tracked · source-linked performance, management guidance and promise context.

Research layer active
PositiveCredibility 0/100Latest record q1-fy27

Latest revenue

₹127 Cr

verified financial record

Quarters tracked

4

source records in the directory

Delivery assessment

0

Across 5 tracked commitments: 0 delivered, 5 missed.

Call date

2026-07-30

latest available source date

Signal trajectory

3 actual quarters
EBITDA (₹ Cr)PositiveWatchNegative
3 actual records
Actual quarterly EBITDA (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q2 FY26: 41 · Positive source sentiment · 2025-11-06Q2 FY26Q3 FY26: 51 · Positive source sentiment · 2026-02-10Q3 FY26Q1 FY27: 46 · Positive source sentiment · 2026-07-30Q1 FY275141
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Current read

0/100

Across 5 tracked commitments: 0 delivered, 5 missed.

Latest source read

What changed this quarter?

Open quarter read

Brigade Hotel Ventures reported resilient Q1 FY27 results with PAT doubling to ₹17 crore (up 140% YoY), driven primarily by a 50%+ reduction in finance costs following aggressive debt repayment post-IPO. Revenue grew 5% to ₹131 crore despite a ₹14 crore impact (10% of revenue) from West Asia geopolitical disruptions that dampened international travel and MICE activity. Management demonstrated operational agility by pivoting to domestic corporate accounts, resulting in 7% ARR growth and 9% RevPAR expansion—signaling pricing power rather than cyclical demand riding. EBITDA margin expanded 120bps to 34.8%, though GST 2.0 created a 160bps headwind. Five of nine hotels are running above 80% occupancy, providing upside optionality. The ₹3,600 crore pipeline (1,700 keys to reach 3,300 total) remains on track, with Grand Hyatt facing minor approval delays. Guidance for mid-teens revenue growth FY27 intact, with Q2-Q4 recovery expected to offset Q1 weakness. Key risk: MICE softness persists and FDA mix decline to 30% from prior 40% creates ADR pressure.

Colored figures compare against the previous available record. Hover or focus one for the comparison.

Signal

Positive

Revenue

₹127 Cr

Source date

2026-07-30

Across the record

Quarter history.

3 source records

History modules

Follow the numbers and themes.